A Phase II trial of liver cancer treatment ThermoDox will kick off worldwide in the second half of this year, biotech firm Celsion announced. New York's Albert Einstein College of Medicine will participate in the randomized study, which will focus on the efficacy of ThermoDox in treating liver cancer and tumors when combined with radiofrequency therapy.

Related Summaries